Placed for the third consecutive year under the High Patronage of Mr Emmanuel Macron, President of the French Republic, the HealthTech Innovation Days (HTID®) will take place in the presence of several institutional representatives: M. Thierry Breton, European Commissioner for the Internal Market, Mrs Alexandra Dublanche, Vice-President of the Île-de-France Regional Council, Mrs Agnès Pannier-Runacher, Minister for Industry, M. Christian Pierret Christian Pierret, former Minister for Industry, M. Laurent Saint-Martin, General Rapporteur of the National Assembly's Finance Committee, M. Alain Godard, CEO of the European Investment Fund and M. Jan-Philipp Beck, CEO of EIT Health.
HTID® will bring together more than 500 inperson participants, including : international investors including Abingworth Management Limited, Baillie Gifford, Bain Capital Public Equity, LP, Emerson Collective, Exor, Forbion, General Atlantic, Invus, KKR, Kreos, Medicxi Ventures, New Enterprise Associates (NEA), Novo Holdings, PSP Investments, Redmile, Sectoral Asset Management, Sofinnova and Temasekand along with more than 150 European companies from more than 20 countries, as well as remote participants. The renewed confidence of its sponsors and the commitment of new partners attest the growing mobilisation of the health ecosystem in Europe.
One year following the opening speech of Mr Emmanuel Macron, President of the French Republic, at the HealthTech Innovation Days 2020, the 2021 edition will detail the economic and financial solutions put in place to face the consequences of the Covid-19 pandemic. In this context, experts will present the concrete means developed to increase the value of European health companies for investors and industrial partners.
Several speakers will share their views during the scheduled round-tables, including:
- "Empower innovation in Healthtech to foster post pandemic EU's economic growth" Session moderated by Christian Pierret, Former French Minister of Industry who will review the role of innovation as an economic lever for the post-crisis period. This round table will take place on Monday 4 October from 1 pm to 1:55 pm: https://htfc-eu.com/agenda-htid/
- "Industrial redevelopment in Europe, where to start?” The speakers of the Round Table with Marc Dechamps, (CEBR Board President & Moderator of the session) will discuss the possibilities to relocate our health industry in Europe. On this occasion the CEBR (Council of European BioRegions) and EIT Health will present the findings of an innovative pan-European study on biomanufacturing issues. This round table will take place on Monday 4 October from 2:00 pm to 2:55 pm: https://htfc-eu.com/agenda-htid/
- "How are disruptive technologies transforming the oncology landscape to fulfill patients' unmet needs?” This panel, presented by Philippe Therasse, Vice-President late stage and life cycle management oncology, Servier (Moderator), will address the cross-cutting needs of cancer patients. This panel will take place on Tuesday 5 October from 2:00 pm to 3:00 pm: : https://htfc-eu.com/agenda-htid/
- "Infectious disease: emerging challenges in the pandemic era". The roundtable discussion moderated by Florence Séjourné, CEO, DA VOLTERRA & President at BEAM Alliance (Moderator), will reveal how the health crisis has cast a new light on infectious diseases. This round table will take place on Tuesday 5 October from 11:30 am to 12:30 pm: https://htfc-eu.com/agenda-htid/
In addition, the CEO of the European Investment Fund, Alain Godard, and the EIT Health France and Services & Investments Managing Director, Jean-Marc Bourez, will unveil the names of the selected corporate and venture capital funds of the Venture Centre of Excellence, a co-investment programme cooperated with EIT Health which has benefited from a EUR150 million anchor investment from the European Commission. The latter was announced at HTID in October 2020 by Mr. Thierry Breton, European Commissioner for the Internal Market. Consequently, the VCoE programme currently holds a total investment capacity of EUR1.7 billion.
Other highlights will bring together international experts on central themes such as the use of AI, advances in robotics, the importance of human capital, the key involvement of patients and associations in the development of new care and finally the added value in the mastery of clinical data processing.
HTID®, which promotes a new culture of innovation based on collaboration, is pleased to count among its patrons major global pharmaceutical groups such as Amgen, Bristol Myers Squibb, Microsoft, Sanofi, Servier, influential players in healthtech, such as Alpha Bue Ocean, BNP Paribas, Dechert, Financière Arbevel, Icosa, Invest Securities, Jeito Capital, McDermott Will & Emery, Rothschild&Co, Sofinnova Partners, Thermo Fisher Scientific as well as institutional partners such as Bpifrance, Euronext and Leem (Les Entreprises du Médicament).
This year HTID® will privilege a face-to-face format while maintaing virtual sessions, allowing for more than 80 international experts to speak about the economic, health and technological challenges facing the healthcare industry in order to accelerate patient access to innovative treatments in Europe.
For more information: https://htfc-eu.com/htid/